African trypanosomiasis: Changing epidemiology and consequences

Current Infectious Disease Reports

Volumn 7, Issue 1, 2005, Pages 54-60

  Chretien, Jean Paul ^b   Smoak, Bonnie L ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTITRYPANOSOMAL AGENT; DB 289; EFLORNITHINE; MELARSOPROL; NIFURTIMOX; PENTAMIDINE; PREDNISOLONE; SURAMIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABSCESS; AFRICAN TRYPANOSOMIASIS; ANOREXIA; ARTICLE; BODY FLUID; BONE MARROW TOXICITY; BRAIN DISEASE; CHAGAS DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DIZZINESS; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; EXFOLIATIVE DERMATITIS; FATALITY; GEOGRAPHIC DISTRIBUTION; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; HYPOGLYCEMIA; HYPOTENSION; IMMIGRANT; INFECTION CONTROL; INFECTION RISK; INJECTION PAIN; MEDICAL EXAMINATION; NAUSEA; NEPHROTOXICITY; PATIENT COUNSELING; PREVENTIVE HEALTH SERVICE; PROTEINURIA; PRURITUS; SEIZURE; SHORT COURSE THERAPY; STAGING; THROMBOCYTOPENIA; TOURISM; TRAVEL; TREATMENT FAILURE; TRYPANOSOMA; TSETSE FLY; VOMITING;

EID: 13544274438     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-005-0024-y     Document Type: Article

References (37)

1. World Health Organization: African Trypanosomiasis. In WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases. Geneva, Switzerland: World Health Organization; 2000. http://www.who.int/emc-documents/surveillance/docs/whocdscsrisr2001.html/ African_Trypanosomiasis/A_Trypanosomiasis.htm
2. Moore A: Human African trypanosomiasis: a reemerging public health threat. In Emerging Infections, edn 6. Edited by Scheld WM, Murray BE, Hughes JM. Washington, DC: ASM Press; 2004:143-157.
3. Magnus E, Vervoort T, Van Meirvenne N: A card-agglutination test with stained trypanosomes (C.A.T.T.) for the serological diagnosis of T.B. gambiense trypanosomiasis. Ann Soc Belg Med Trop 1978, 58:169-176.
4. Abel PM, Kiala G, Loa V, et al.: Retaking sleeping sickness control in Angola. Trop Med Int Health 2004, 9: 41-148.
5. Stanghellini A, Josenando T: The situation of sleeping sickness in Angola: a calamity. Trop Med Int Health 2001, 6: 30-334.
6. Moore A, Richer M: Re-emergence of epidemic sleeping sickness in southern Sudan. Trop Med Int Health 2001, 6: 42-347.
7. Van Nieuwenhove S, Betu-Ku-Mesu VK, Diabakana PM, et al. Sleeping sickness resurgence in the DRC: the past decade. Trop Med Int Health 2001, 6:335-341.
8. Robays J, Ebeja Kadima A, Lutumba P, et al.: Human African trypanosomiasis amongst urban residents in Kinshasa: a case-control study. Trop Med Int Health 2004, 9:869-875.
9. Hutchinson OC, Fevre EM, Carrington M, Welburn SC: Lessons learned from the emergence of a new Trypanosoma brucei rhodesiense sleeping sickness focus in Uganda. Lancet Infect Dis 2003, 3: 2-45.
10. Waiswa C, Olaho-Mukani W, Katunguka-Rwakishaya E: Domestic animals as reservoirs for sleeping sickness in three endemic foci in south-eastern Uganda. Ann Trop Med Parasitol 2003, 97: 49-155.
11. Lejon V, Boelaert M, Jannin J, et al.: The challenge of Trypanosoma brucei gambiense sleeping sickness diagnosis outside Africa. Lancet Infect Dis 2003, 3:804-808.
12. Jelinek T, Bisoffi Z, Bonazzi L, et al.: Cluster of African trypanosomiasis in travelers to Tanzanian national parks. Emerg Infect Dis 2002, 8:634-635.
13. Lejon V, Sindic CJ, Van Antwerpen MP, et al.: Human African trypanosomiasis: quantitative and qualitative assessment of intrathecal immune response. Eur J Neurol 2003, 10: 11-719.
14. Burri C, Brun R: Human African trypanosomiasis. In Manson's Tropical Diseases, edn 21. Edited by Cook GC, Zumla A. London: WB Saunders Company; 2003:1303-1323.
15. Stich A, Abel PM, Krishna S: Human African trypanosomiasis. BMJ 2002, 325:203-206.
16. Kennedy PG: Human African trypanosomiasis of the CNS: current issues and challenges. J Clin Invest 2004, 113: 96-504.
17. Buguet A, Bourdon L, Bouteille B, et al.: The duality of sleeping sickness: focusing on sleep. Sleep Med Rev 2001, 5:139-153.
18. Lumsden WH, Kimber CD, Dukes P, et al.: Field diagnosis of sleeping sickness in the Ivory Coast. I. Comparison of the miniature anion-exchange/centrifugation technique with other protozoological methods. Trans R Soc Trop Med Hyg 1981, 75: 42-250.
19. Bailey JW, Smith DH: The use of the acridine orange QBC technique in the diagnosis of African trypanosomiasis. Trans R Soc Trop Med Hyg 1992, 86:630.
20. World Health Organization: Control and surveillance of African trypanosomiasis. World Health Organ Tech Rep Ser 1998, 881:1-114.
21. Truc P, Aerts D, McNamara JJ, et al.: Direct isolation in vitro of Trypanosoma brucei from man and other animals, and its potential value for the diagnosis of gambian trypanosomiasis. Trans R Soc Trop Med Hyg 1992, 86:627-629.
22. Magnus E, Lejon V, Bayon D, et al.: Evaluation of an EDTA version of CATT/Trypanosoma brucei gambiense for serological screening of human blood samples. Acta Trop 2002, 81:7-12.
23. Penchenier L, Simo G, Grebaut P, et al.: Diagnosis of human trypanosomiasis, due to Trypanosoma brucei gambiense in central Africa, by the polymerase chain reaction. Trans R Soc Trop Med Hyg 2000, 94:392-394.
24. Jamonneau V, Solano P, Garcia A, et al.: Stage determination and therapeutic decision in human African trypanosomiasis: value of polymerase chain reaction and immunoglobulin M quantification on the cerebrospinal fluid of sleeping sickness patients in Cote d'Ivoire. Trop Med Int Health 2003, 8:589-594.
25. Lejon V, Legros D, Richer M, et al.: IgM quantification in the cerebrospinal fluid of sleeping sickness patients by a latex card agglutination test. Trop Med Int Health 2002, 7:685-692.
26. Pepin J, Milord F: The treatment of human African trypanosomiasis. Adv Parasitol 1994, 33:1-47.
27. Pepin J, Milord F, Khonde AN, et al.: Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg 1995, 89:92-97.
28. Pepin J, Milord F, Khonde A, et al.: Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy. Trans R Soc Trop Med Hyg 1994, 88: 47-452.
29. Schmid C, Nkunku S, Merolle A, et al.: Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness. Lancet 2004, 364:789-790.
30. Legros D, Evans S, Maiso F, et al.: Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg 1999, 93: 39-442.
31. Burri C, Keiser J: Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment. Trop Med Int Health 2001, 6:412-420.
32. Iten M, Matovu E, Brun R, Kaminsky R: Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-alpha-difluoromethylornithine (DFMO). Trop Med Parasitol 1995, 46:190-194.
33. Bouteille B, Oukem O, Bisser S, Dumas M: Treatment perspectives for human African trypanosomiasis. Fundam Clin Pharmacol 2003, 17:171-181.
34. Centers for Disease Control and Prevention: African trypanosomiasis (African sleeping sickness). In The Yellow Book. Health Information for International Travel, 2003-2004. Atlanta, GA: US Department of Health and Human Services, Public Health Service; 2004:45-46. http://www.cdc.gov/travel/diseases/afrtrypano.htm.
35. Pepin J: African trypanosomiasis. In Hunter's Tropical Medicine and Emerging Infectious Diseases, edn 8. Edited by Strickland GT. Philadelphia: WB Saunders Company; 2000:643-653.
36. Kirchhoff LV: Agents of African trypanosomiasis (sleeping sickness). In Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, vol 2, edn 5. Edited by Mandell GL, Bennett JE, Dolin R. Philadelphia: Churchill Livingstone; 2000:2853-2858.
37. The Medical Letter on Drugs and Therapeutics: Drugs for Parasitic Infections. New Rochelle, NY: The Medical Letter Inc.; 2002.